The table below lists the number of stem cell trans­plants carried out at U.S. multiple myeloma treat­ment centers and other U.S. cancer centers in 2017, the most recent year for which such statistics are avail­able.

The results in the table can be sorted in ascending or descending order by click­ing on column head­ings. More than one column can be used to sort the results by hold­ing down the shift key when click­ing on a second or any sub­se­quent column for addi­tional sort­ing.

Values in columns labeled "MM" are for patients who have had a multiple myeloma diag­nosis. Values for "MM + Other" are for people with multiple myeloma or one of several other dis­eases which, to­gether, account for most of the au­tol­o­gous (own) or allo­geneic (donor) stem cell trans­plants at U.S. cancer centers.

Please see the explanatory notes below the table for further in­for­ma­tion about the table contents, in­clud­ing data sources and details about the results in the dif­fer­en­t columns of the table.

Number Of Stem Cell Transplants
Carried Out At U.S. Cancer Centers In 2017

Explanatory Notes

The table above in­cludes data related to au­tol­o­gous (own) stem cell trans­plants and allo­geneic (donor) stem cell trans­plants.

For each type of trans­plant, two numbers are listed.

The first number, labeled “MM,” is the number of au­tol­o­gous or allo­geneic trans­plants carried out in people with multiple myeloma.

The second number, labeled “MM + Other,” is the number of au­tol­o­gous or allo­geneic trans­plants carried out in multiple myeloma patients and patients with other dis­eases. (See below for more about what "other dis­eases" are in­cluded for each type of trans­plant.)

The pur­pose of the second number is to give a sense of how often individual treat­ment centers per­form au­tol­o­gous or allo­geneic trans­plants in general, rather than specifically for multiple myeloma. This could be a con­sid­er­a­tion, for example, in the case of allo­geneic stem cell trans­plants, which are not common in the case of multiple myeloma, but which some centers carry out frequently for patients with other dis­eases.

More About The '"MM" + Other' Columns

It is worth noting that the “MM + Other” data in the table account for most, but not all, of the au­tol­o­gous and allo­geneic trans­plants carried out in 2017 at each center listed in the table. That is, the “MM + Other” data are not quite “MM + All Other,” but rather “MM + Most Other.”

• In the case of autologous (own) stem cell transplants, “MM + Other” is the number of autologous transplants carried out in patients with either multiple myeloma, Hodgkin lymphoma, or non-Hodgkin lymphoma. From 2012 to 2016, autologous transplants for patients with these three diseases accounted for 89 percent of all autologous transplants carried out in the United States.
• In the case of allogeneic (donor) stem cell transplants, the “MM + Other” data are for transplants carried out at each center in patients with either multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma, myelodysplastic syndromes (MDS), non-Hodgkin lymphoma, or severe aplastic anemia. From 2012 to 2016, allogeneic transplants for patients with these seven diseases accounted for 80 percent of all allogeneic transplants carried out in the United States.

Please note that the results in the table reflect the number of transplants per­formed in 2017, not the number of patients receiving trans­plants. A single patient who has two au­tol­o­gous trans­plants at the same center in a single year will con­trib­ute two trans­plants to the center's total number of au­tol­o­gous trans­plants for the year, not one.

Data Source, Treatment Center Names, And Excluded Centers

The data presented in the table were compiled by The Myeloma Beacon based on statistics collected by the Center for Inter­na­tional Blood and Marrow Transplant Research. Cancer centers in the United States are required by law to report statistics related to allo­geneic (donor) stem cell trans­plants. Most centers also report such statistics for au­tol­o­gous stem cell trans­plants.

The treat­ment center names listed in the table are in some cases dif­fer­en­t than the names commonly used to refer to individual centers. The names in the table are, how­ever, the ones used in the original data The Beacon used to develop the table.

Children’s hos­pi­tals are not in­cluded in the table because no multiple myeloma-related trans­plants were carried out at such centers in 2017.

Also, some cancer centers file two sets of trans­plant statistics each year: one for adult patients, and one for pedi­atric patients. For those centers, only the adult statistics are in­cluded below because, once again, no myeloma patients were reported as receiving trans­plants in 2017 in the pedi­atric data for centers reporting adult and pedi­atric data separately.

Finally, data for the fol­low­ing centers are not in­cluded in the table above because their results were not reported in time, or could not be val­i­dated in time, for them to in­cluded in the source data used by The Myeloma Beacon to create the table:

• Alta Bates Comprehensive Cancer Center (California)
• Medical Oncology Hematology Consultants, PA (Delaware)
• Baptist Hospital of Miami (Florida)
• Rejuva Stem Cell Center LLC (Florida)
• NYU Winthrop Hospital (New York)
• Novant Health Transplantation and Cellular Therapy Program (North Carolina)
• Pediatric Immunology Bone Marrow Transplant Center (North Carolina)
• Pennsylvania Hospital (Pennsylvania)
• Hospital Auxilio Mutuo (Puerto Rico)
• The Center for Blood Disorders and Stem Cell Transplantation (Washington)
• Marshfield Clinic Health Systems (Wisconsin)